An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL

Jin-Shei Lai*, Jennifer L. Beaumont, Sally Elizabeth Jensen, Karen Kaiser Tegel, David L. Van Brunt, Amy H. Kao, Shih Yin Chen

*Corresponding author for this work

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is a multi-organ chronic autoimmune disease that can negatively affect patients’ health-related quality of life (HRQOL). This study evaluated HRQOL of SLE patients using questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) and Quality of Life in Neurological Disorders (Neuro-QoL). Individuals with SLE completed an online survey consisting of the PROMIS-29 health profile, PROMIS Psychosocial Illness Impact-Negative, and Neuro-QoL Applied Cognition. PROMIS and Neuro-QoL scores have a mean of 50 in the US general population. Patients self-rated SLE disease severity as negligible, mild, moderate, or severe. Of the 333 participants (mean age 45 years; 92% female; 26% Black; mean SLE disease duration 12 years, 56% with SLE disease severity as moderate or severe), mean HRQOL scores were worse than those of the general population by ≥0.5 SD with the greatest deficits observed in the domains of fatigue, applied cognition, psychosocial illness impact-negative, pain interference, and physical function. Greater SLE disease severity was associated with worse mean HRQOL scores (all p < 0.05). Pain severity was also associated with worse HRQOL scores on all domains (p < 0.05) except for satisfaction with social role. Test-retest reliability exceeded 0.70 for all PROMIS and Neuro-QoL scores. PROMIS-29 and Neuro-QoL are valid tools to assess HRQOL in patients with SLE. These patients reported substantial deficits that correlated with their SLE disease severity, with pain being an important independent contributor. These deficits should be monitored in SLE patients during their routine clinical care and evaluated when investigating new therapies.

Original languageEnglish (US)
Pages (from-to)555-562
Number of pages8
JournalClinical Rheumatology
Volume36
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Information Systems
Systemic Lupus Erythematosus
Quality of Life
Pain
Cognition
Patient Reported Outcome Measures
Health Information Systems
Nervous System Diseases
Reproducibility of Results
Population
Autoimmune Diseases
Fatigue
Chronic Disease

Keywords

  • Neuro-QoL
  • PROMIS
  • Patient-reported outcomes
  • SLE-rheumatic diseases

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{c17825eb01b544f582217eeb56195181,
title = "An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL",
abstract = "Systemic lupus erythematosus (SLE) is a multi-organ chronic autoimmune disease that can negatively affect patients’ health-related quality of life (HRQOL). This study evaluated HRQOL of SLE patients using questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) and Quality of Life in Neurological Disorders (Neuro-QoL). Individuals with SLE completed an online survey consisting of the PROMIS-29 health profile, PROMIS Psychosocial Illness Impact-Negative, and Neuro-QoL Applied Cognition. PROMIS and Neuro-QoL scores have a mean of 50 in the US general population. Patients self-rated SLE disease severity as negligible, mild, moderate, or severe. Of the 333 participants (mean age 45 years; 92{\%} female; 26{\%} Black; mean SLE disease duration 12 years, 56{\%} with SLE disease severity as moderate or severe), mean HRQOL scores were worse than those of the general population by ≥0.5 SD with the greatest deficits observed in the domains of fatigue, applied cognition, psychosocial illness impact-negative, pain interference, and physical function. Greater SLE disease severity was associated with worse mean HRQOL scores (all p < 0.05). Pain severity was also associated with worse HRQOL scores on all domains (p < 0.05) except for satisfaction with social role. Test-retest reliability exceeded 0.70 for all PROMIS and Neuro-QoL scores. PROMIS-29 and Neuro-QoL are valid tools to assess HRQOL in patients with SLE. These patients reported substantial deficits that correlated with their SLE disease severity, with pain being an important independent contributor. These deficits should be monitored in SLE patients during their routine clinical care and evaluated when investigating new therapies.",
keywords = "Neuro-QoL, PROMIS, Patient-reported outcomes, SLE-rheumatic diseases",
author = "Jin-Shei Lai and Beaumont, {Jennifer L.} and Jensen, {Sally Elizabeth} and Tegel, {Karen Kaiser} and {Van Brunt}, {David L.} and Kao, {Amy H.} and Chen, {Shih Yin}",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s10067-016-3476-6",
language = "English (US)",
volume = "36",
pages = "555--562",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "3",

}

An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL. / Lai, Jin-Shei; Beaumont, Jennifer L.; Jensen, Sally Elizabeth; Tegel, Karen Kaiser; Van Brunt, David L.; Kao, Amy H.; Chen, Shih Yin.

In: Clinical Rheumatology, Vol. 36, No. 3, 01.03.2017, p. 555-562.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL

AU - Lai, Jin-Shei

AU - Beaumont, Jennifer L.

AU - Jensen, Sally Elizabeth

AU - Tegel, Karen Kaiser

AU - Van Brunt, David L.

AU - Kao, Amy H.

AU - Chen, Shih Yin

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Systemic lupus erythematosus (SLE) is a multi-organ chronic autoimmune disease that can negatively affect patients’ health-related quality of life (HRQOL). This study evaluated HRQOL of SLE patients using questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) and Quality of Life in Neurological Disorders (Neuro-QoL). Individuals with SLE completed an online survey consisting of the PROMIS-29 health profile, PROMIS Psychosocial Illness Impact-Negative, and Neuro-QoL Applied Cognition. PROMIS and Neuro-QoL scores have a mean of 50 in the US general population. Patients self-rated SLE disease severity as negligible, mild, moderate, or severe. Of the 333 participants (mean age 45 years; 92% female; 26% Black; mean SLE disease duration 12 years, 56% with SLE disease severity as moderate or severe), mean HRQOL scores were worse than those of the general population by ≥0.5 SD with the greatest deficits observed in the domains of fatigue, applied cognition, psychosocial illness impact-negative, pain interference, and physical function. Greater SLE disease severity was associated with worse mean HRQOL scores (all p < 0.05). Pain severity was also associated with worse HRQOL scores on all domains (p < 0.05) except for satisfaction with social role. Test-retest reliability exceeded 0.70 for all PROMIS and Neuro-QoL scores. PROMIS-29 and Neuro-QoL are valid tools to assess HRQOL in patients with SLE. These patients reported substantial deficits that correlated with their SLE disease severity, with pain being an important independent contributor. These deficits should be monitored in SLE patients during their routine clinical care and evaluated when investigating new therapies.

AB - Systemic lupus erythematosus (SLE) is a multi-organ chronic autoimmune disease that can negatively affect patients’ health-related quality of life (HRQOL). This study evaluated HRQOL of SLE patients using questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) and Quality of Life in Neurological Disorders (Neuro-QoL). Individuals with SLE completed an online survey consisting of the PROMIS-29 health profile, PROMIS Psychosocial Illness Impact-Negative, and Neuro-QoL Applied Cognition. PROMIS and Neuro-QoL scores have a mean of 50 in the US general population. Patients self-rated SLE disease severity as negligible, mild, moderate, or severe. Of the 333 participants (mean age 45 years; 92% female; 26% Black; mean SLE disease duration 12 years, 56% with SLE disease severity as moderate or severe), mean HRQOL scores were worse than those of the general population by ≥0.5 SD with the greatest deficits observed in the domains of fatigue, applied cognition, psychosocial illness impact-negative, pain interference, and physical function. Greater SLE disease severity was associated with worse mean HRQOL scores (all p < 0.05). Pain severity was also associated with worse HRQOL scores on all domains (p < 0.05) except for satisfaction with social role. Test-retest reliability exceeded 0.70 for all PROMIS and Neuro-QoL scores. PROMIS-29 and Neuro-QoL are valid tools to assess HRQOL in patients with SLE. These patients reported substantial deficits that correlated with their SLE disease severity, with pain being an important independent contributor. These deficits should be monitored in SLE patients during their routine clinical care and evaluated when investigating new therapies.

KW - Neuro-QoL

KW - PROMIS

KW - Patient-reported outcomes

KW - SLE-rheumatic diseases

UR - http://www.scopus.com/inward/record.url?scp=84995460721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995460721&partnerID=8YFLogxK

U2 - 10.1007/s10067-016-3476-6

DO - 10.1007/s10067-016-3476-6

M3 - Article

VL - 36

SP - 555

EP - 562

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 3

ER -